Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $130.45 USD
Change Today +1.45 / 1.12%
Volume 245.6K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 1:14 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Expects to Submit a New Drug Application for crisaborole to the U.S. Food and Drug Administration in the First Half of 2016

Anacor Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $21,337,000 compared to $2,931,000 a year ago. Loss from operations was $11,996,000 compared to $23,425,000 a year ago. Net loss was $13,196,000 or $0.30 per basic and diluted share compared to $24,508,000 or $0.58 per basic and diluted share a year ago. Recognized $17.8 million in total KERYDIN revenue in the second quarter of 2015 under the Sandoz Agreement, representing a sequential increase of 47.5% over the first quarter of 2015. For the six months, the company reported total revenues of $36,601,000 compared to $7,089,000 a year ago. Loss from operations was $23,792,000 compared to $43,530,000 a year ago. Net loss was $26,157,000 or $0.60 per basic and diluted share compared to $45,680,000 or $1.09 per basic and diluted share a year ago. The company expects to submit a new drug application for crisaborole to the U.S. Food and Drug Administration in the first half of 2016.

Anacor Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Anacor Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Daylight on Aug 06, 2015

Anacor Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Anacor Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Anacor Pharmaceuticals, Inc. Announces Preliminary Top-Line Results from its Two Phase 3 Pivotal Studies of Crisaborole Topical Ointment

Anacor Pharmaceuticals, Inc. announced preliminary top-line results from its two Phase 3 pivotal studies of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. In both studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies. Atopic dermatitis is a chronic rash characterized by inflammation and itching. Lesions of atopic dermatitis are commonly red, elevated and oozing patches and are often accompanied by pruritus (itching). The lesions' lichenification, a thickening of the skin with exaggerated skin lines, is considered to be a hypertrophic response to chronic rubbing. Based on available sources, the company believe approximately 18 to 25 million people in the United States suffer from atopic dermatitis, and 80% to 90% have mild or moderate disease. Atopic dermatitis can persist into adulthood, but most commonly appears in childhood, with estimates that between 8% and 18% of all infants and children in the United States are affected by the disease.

Anacor Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 12:45 PM

Anacor Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 12:45 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Paul L. Berns, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $130.45 USD +1.45

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 113.9x
Price/Book 87.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 109.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.